GlassScriptPhysician profile
Daniel Matthew Henbest
NPI 1235540865
$1,189.57
in general payments reported to CMS, 2019-2025
28 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $161 · 2021: $378 · 2022: $133 · 2023: $31.26 · 2024: $97.74 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252.44 | 2021-2025 | |
| Novo Nordisk INC | $150.90 | 2019-2022 | |
| Lilly USA, LLC | $62.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $60.40 | 2021-2022 | |
| Axsome Therapeutics, INC. | $59.37 | 2024 | Auvelity |
| Abbott Laboratories | $58.49 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.65 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $54.05 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $39.75 | 2025 | Daybue |
| Astrazeneca Pharmaceuticals LP | $37.94 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.80 | 2019-2020 | |
| Glaxosmithkline, LLC. | $29.44 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $26.80 | 2021 | |
| Merck Sharp & Dohme LLC | $26.31 | 2021-2022 | |
| Amgen INC. | $22.06 | 2025 | Evenity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.08 | 2021 | |
| Horizon Therapeutics Plc | $20.68 | 2019 | |
| Exact Sciences Corporation | $20.33 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $20.28 | 2020 | |
| Ibsa Pharma INC. | $19.31 | 2024 | Flector, Licart, Tirosint |
| Insulet Corporation | $19.06 | 2024 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $18.72 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.09 | 2019 | |
| Eisai INC. | $16.15 | 2021 | |
| Therapeuticsmd, INC. | $16.04 | 2021 | |
| Pfizer INC. | $14.45 | 2020 | |
| Corium, LLC | $10.93 | 2023 | Azstarys |
| Phathom Pharmaceuticals, INC. | $7.30 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Henbest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.